-
Puma Biotechnology Boosted After FDA Approves Breast Cancer Therapy
Tuesday, July 18, 2017 - 8:25am | 397Read More...The U.S. Food and Drug Administration on Monday approved Puma Biotechnology Inc (NASDAQ: PBYI)'s NERLYNX (neratinib), formerly known as PB272, for the treatment of breast cancer. Neratinib is the first anti-HER2 treatment to gain the FDA's approval for extended adjuvant therapy for early-...
-
The Current State Of The Breast Cancer Treatment Space
Tuesday, May 23, 2017 - 8:59am | 703Read More...Puma Biotechnology Inc (NASDAQ: PBYI) popped 88 percent Monday on news that its neratinib candidate, an early-stage breast cancer treatment for human epidermal growth factor receptor-2 (HER2) positive mutations, was advancing in the U.S. Food and Drug Administration investigatory process. For...
-
Merrimack Stops Phase 2 Study Of Breast Cancer Drug, Shares Lose 20%
Wednesday, December 21, 2016 - 8:44am | 307Read More...Shares of Merrimack Pharmaceuticals Inc (NASDAQ: MACK) fell more than 20 percent early Wednesday morning after the company announced that it will stop a Phase 2 study of its treatment to fight breast cancer. The Phase 2 study was called HERMIONE and evaluated its only drug MM-302, an antibody-...
-
Thursday's After-Hours Movers: Zumiez, Puma Biotech, Finisar And More
Thursday, September 10, 2015 - 4:43pm | 325Read More...Shares of Zumiez Inc. (NASDAQ: ZUMZ) fell 3.56 percent on Thursday and another 18 percent after hours following its earnings call. The small-cap multi-channel specialty retailer reported Q2 earnings of $0.12 per share on revenue of $179.82 million, in line with the Street’s consensus, but...
